Biocon gets DCGI nod to market biosimilar trastuzumab in India

NEW DELHI: Biotechnology major BioconBSE 3.39 % today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.

“The company has received market authorisation from the Drug Controller General of India (DCGI) for its biosimilar trastuzumab being developed jointly with Mylan for the treatment of Her 2+ metastatic breast cancer,” Biocon said in a state ..

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s